Sandeep Sahay

Associate Professor

Houston Methodist Hospital

United States

Research Interests

Explore related searches

Professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Dr. Sandeep Sahay is an Associate Professor at Houston Methodist Hospital in the United States. His research focuses on pulmonary arterial hypertension, exploring topics such as treatment strategies, risk stratification, and associated comorbidities. Dr. Sahay has contributed to recent studies on therapies and real-world experiences, notably concerning seralutinib and sotatercept. His work aims to advance understanding and care for patients with pulmonary hypertension and related conditions.

Articles (20)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Collaborators (7)

Sudarshan Rajagopal

UNITED STATES

View details

Ioana Preston

Associate Professor of Medicine

Tufts Medical Center

UNITED STATES

View details

Jose Benjamin Cruz Rodriguez

Assistant Clinical Professor

University of California, San Diego

UNITED STATES

View details

Olivier SITBON

FRANCE

View details

Nils P. Nickel

UNITED STATES

View details

Nick H. Kim

UNITED STATES

View details

Eric D. Austin

Vanderbilt University Medical Center

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Sandeep Sahay

Research Interests

Explore related searches

Contact this professor

About

Articles (20)

International Society for Heart and Lung Transplantation (ISHLT) Consensus Statement on Risk Stratification in Pulmonary Arterial Hypertension

Seralutinib for the Treatment of Pulmonary Arterial Hypertension in Adults: TORREY Open-Label Extension Study

Pericardial Effusions And Sotatercept Therapy in Pulmonary Arterial Hypertension: A Multicenter Real-World Experience

Frailty in Pulmonary Hypertension: A Multidimensional Comorbidity

A Twist in the Fibrotic Tale: The Overlooked Vasculopathy in Idiopathic Pulmonary Fibrosis

Rethinking pulmonary arterial hypertension care: the role of dual therapy in patients with cardiovascular comorbidities

Pulmonary Tumor Thrombotic Microangiopathy

Stratifying risk in pulmonary arterial hypertension: Should we expect more?

A new day has come: Sotatercept for the treatment of pulmonary arterial hypertension

Contemporary Treatment of Pulmonary Arterial Hypertension: A U.S. Perspective

Prognosis in Hispanic patient population with pulmonary arterial hypertension: An application of common risk stratification models

Safety and efficacy of transitioning from selexipag to oral treprostinil in pulmonary arterial hypertension

The Role of Cascade Screening in Heritable Forms of Pulmonary Arterial Hypertension

The role of riociguat in combination therapies for pulmonary arterial hypertension

Insulin‐like growth factor binding protein‐4: The quest for the breakthrough biomarker in pulmonary arterial hypertension

Inhaled Treprostinil Dosage in Pulmonary Hypertension Associated With Interstitial Lung Disease and Its Effects on Clinical Outcomes

Effects of COVID-19 pandemic on the management of pulmonary hypertension

Barriers and facilitators to interhospital transfer of acute pulmonary embolism

INSPIRE: Safety and tolerability of inhaled Yutrepia (treprostinil) in pulmonary arterial hypertension (PAH)

Screening Strategies for Pulmonary Hypertension in Patients With Interstitial Lung Disease

Collaborators (7)

Sudarshan Rajagopal

Ioana Preston

Jose Benjamin Cruz Rodriguez

Olivier SITBON

Nils P. Nickel

Nick H. Kim

Eric D. Austin

Make your next move.